

Keyword index to Volume 84

Key to abbreviations:

(Suppl 1) Supplement 1; (Suppl 2) Supplement 2

- Aberrant crypt foci 90
N-Acetylcysteine 558
 Acinar cancer 253
 Acute lymphoblastic leukaemia 11
 Acute myeloid leukaemia 680
 Adenocarcinomas 813, 969, 1199
 Adenomas 1354
 Adenovirus 1252
 ADEPT 1671
 Adhesive molecules 802
 Adjuvant chemotherapy 186, 878
 Adjuvant therapy 263, 1146
 Administration routes 1564
 β -Adrenergic receptors 1648
 Adults 1193
 Advanced breast cancer 1172
 Advanced colorectal cancer 651, 1023
 Advanced Hodgkin's disease 1293
 Adverse effects 697
 AG2034 308
 Allelotypes 321
 Allelotyping 253
 All-*trans* retinoic acid 1571
 Alternating chemotherapy 1293
 Alternative opioids 587
 Alternative splicing event 1087
 Alveolar type II pneumocytes 813
 Amifostine 19, 313
 Aminolevulinic acid 33
 Amphiregulin 936
 Amplification 824
 Ampulla of Vater cancer 253
 Amsterdam criteria 1084
ANA gene 754
 Anaemia 17 (Suppl 1), 24 (Suppl 1), 31 (Suppl 1)
 Analytical variations 1301
 Androgen-independent progression 859
 Androgens 760
 Androgens, and breast cancer 760
 Angiogenesis 626, 832, 844, 1322, 1354
 Animals 1681
 Anthracyclines 550, 1437
 Anthropomorphic factors 1466
 Antiangiogenesis 1252
 Antibodies 1671
 Antibody-directed enzyme prodrug therapy 1253
 Anticancer drugs 100
 Anticancer drug discovery 1424
 Anti-idiotypic antibodies 1443
 Anti-oestrogens 897, 1047
 Anti-oestrogen resistance 686
 Antioxidants 1397
 Antisense oligonucleotides 768
 Antivascular action 565
 Antivascular effects 290
 Anxiety 8
 Axillary lymph nodes 33
 Aphidicolin 680
 Apoptosis 87, 100, 263, 520, 670, 836, 851, 859, 951, 1099, 1126, 1135, 1265, 1272, 1330, 1412, 1551, 1571
 Apoptotic index 651
 Arrays 1512
 Ascorbic acid 1544
 Ashkenazi Jews 475
 Aspirin 965
 Astrocytoma 429
 A49T 1344
 Attitudes 413
 A-type lamins 512
 Atypical hyperplasia 209
 Autocrine 926
 Autologous stem cell transplantations 1348
 Autosomal recessives 429
 Barrett's oesophagus 748
 Basal cell skin carcinomas 512
 Bax expression 651
 BBR 3464 1387
 bcl-2 263, 686, 1397
 bcl-2 expression 651
 bcl-2 homologues 920
 Benign breast lesions 1064
 Benign prostatic hyperplasia 1512
 Betel quid chewing 709
 BID 670
 Bioavailability 42
 Biochemical modulation 1023
 Biochemotherapy 1036
 Biological activity 3 (Suppl 1)
 Biological variations 1301
 Biphosphonates 1126
 Birth weight 1193
 Births 406
 BIS20x3 1115
 Bi-specific antibodies 1115
 Bisphosphonates 951, 1047
 Bladder 270, 1242
 Bladder cancer 321, 558, 1330
 Bleomycin 565, 1272
 Blindness 397
 bmi-1 1372
 Body mass index 975
 Bone marrow endothelium 1417
 Bone metastases 1586
 Bone mineral density 1047
 Bone pain 297
 Bone sialoprotein 344
 BPH 1512
 Brain cancer 990
 Brain metastases 903
 Brain tumours 1107
BRCA1 475, 704
BRCA2 193
BRCA2 475, 478, 704
 Breast cancer 126, 157, 397, 435, 493, 700, 704, 760, 783, 802, 897, 915, 994, 1064, 1095, 1126, 1156, 1188, 1252, 1258, 1348, 1437, 1466, 1472, 1488, 1577, 1591, 1677
 Breast cancer, advanced 1172
 Breast cancer cells 936
 Breast cancer prognosis 760
 Breast cancer screening 423
 Breast feeding 1472
 Breast neoplasms 1047, 1308
 Breast tumours 33
 Breast-conserving therapy 539
 Breast-ovarian cancer 482
 Bryostatins 1 465
BTAK 824
N-Butyldeoxynojirimycin 1107
 B-type lamins 512
 Budding 1317
 Bystander effects 674
 CA 125 1301
 Calpain 946
 Cancer 8, 11 (Suppl 1), 17 (Suppl 1), 24 (Suppl 1), 31 (Suppl 1), 48, 126, 179, 406, 1193, 1207, 1219, 1463
 Cancer cachexia 1135
 Cancer cell invasion metastasis 1664
 Cancer chemotherapy 550
 Cancer gene therapy 1677
 Cancer genetics 435
 Cancer incidences 1215
 Cancer modelling 388
 Cancer risks 594, 1466
 Cancer screening 360
 Cancer *in situ* 791
 Cancer vaccines 915
 Cancers, human 193
 Capecitabine 1437
 Capillary counting 836
 Carbohydrates 3 (Suppl 1)
 Carbohydrate determinants 1258
 Carboplatin 38, 170
 Carcinomas 253, 270, 631, 1076, 1512, 1630
 Carotene 728
 Case-control studies 120, 134, 141, 697, 1472
 Caspases 1135
 Caspase 3 activity 851
 Caspase 9 851
 Castration 859
 Catenins 1656
 β -Catenin 209
 Caudal related homeobox genes 218
 Causes of death 700
 CD20 1115
 CD44 244
 CD44v6 244
 CD55 (DAF) 80
 cDNA array 352
 CDX2 218
CDX2 1314
 Cell cycles 1242, 1372, 1571
 Cell cycle arrest 1640
 Cell growth control *elF3* 1520
 Cell transformation 374
 Cell-cycle G_0/G_1 arrest 768
 c-erbB-2 1377
 c-erbB-3 1377
 c-erbB-4 1377
 Cervical cancer 24 (Suppl 2), 360, 791, 892, 1616
 Cervical dysplasia 796
 Cervical intraepithelial neoplasia 796
 Cervical smears 360
 Cervix 1058, 1219
 CGH 202, 499
 Chemical cleavage of mismatch 482
 Chemoprevention 90
 Chemoprotection 19
 Chemotherapy 11 (Suppl 1), 17 (Suppl 1), 19, 24 (Suppl 1), 31 (Suppl 1), 170, 303, 1150, 1179, 1391, 1447, 1577
 Childhood cancer 141, 413, 1460
 Childhood leukaemia 406, 1002
 Childhood mortality 1460
 Childhood non-Hodgkin's lymphoma 1002
 Children 604, 697, 1215
 Chimeric PCR primers 482
 ChIVPP/PABIOE 1293
 Chromogranin A 636, 808
 Chromosomal location 237
 Chromosomal rearrangement 535
 Chromosome 8 72
 Chromosome 19p13 493
 Chromosome 21 754
 Chromosome aberrations 776, 892
 Chromosome instability 489
 Chronic disease 24 (Suppl 1)
 Chronic hypoxia 1122
 CIN 360
 Circulating tumour cells 631
 Cisplatin 565, 1387

- Clear cell sarcomas 535
 Clinical decision-making 1172
 Clinical Practice Guidelines 1
 (Suppl 2), 4 (Suppl 2), 6
 (Suppl 2)
 Clinical samples 768
 Clinical studies 11 (Suppl 1)
 Clinical trials 1424
 Clonogenic survival 100
 c-Met 864
 c-myc 72
c-myc 813
 Codon 72 polymorphism 739
 Cognitive dissonance reduction
 1577
 Cohorts 113
 Coincidences 1084
 Collagenases 1076
 Colon cancer 66 (Suppl 2), 90,
 844, 1412, 1535
 Colon cancer cell lines 579
 Colon neoplasia 1265
 Colorectal adenocarcinoma
 1354
 Colorectal cancer 94, 196, 218,
 232, 417, 475, 520, 600, 611,
 892, 910, 969, 1314, 1317,
 1443, 1497, 1671
 Colorectal cancer, advanced
 651, 1023
 Colorectal neoplasia 722, 1308,
 1477
 Combination immunotoxin
 therapy 571
 Combined therapy 460
 Combretastatin 832
 Comet assay 1671
 Communications 1011
 Comparative genomic
 hybridization 202, 499
 Conservative surgery 164
 Continuous intravenous infusion
 1043
 Contrast media 1681
 c-Src tyrosine kinase 196
 CTL 94
 Cutaneous melanoma 81
 (Suppl 2)
 Cyclic AMP 1648
 Cyclin B 283
 Cyclin D₁ 270, 1064
 Cyclin E 1242
 Cyclin-dependent kinases 283,
 1391
 Cyclin-dependent kinase 1 283
 Cyclo-oxygenase-2 335
 Cyclophosphamide 1591
 Cyst fluid 1363
 Cytarabine 157
 Cytochrome *c* 1099
 Cytokines 659, 1122
 Cytoprotection 313
 Cytosine arabinoside 680
 Cytotoxic T lymphocytes 1052,
 1564
 Cytotoxicity 106, 1535
 Darbepoetin- α 3 (Suppl 1),
 11 (Suppl 1), 17 (Suppl 1),
 24 (Suppl 1), 31 (Suppl 1)
 De novo carcinoma 1497
 Deglyco-bleomycin-A₂ 1272
 185delAG 475
 Deletions 193
 617delT 475
 Dendritic cells 1564
 5'-Deoxy-5-fluorouridine 1677
 Deoxyuridine 11
 DESC1 237
 Detection mode 423
 Detection of psychiatric
 morbidity 1011
 Dextrazoxane 959
 Diagnosis 406, 1512
 Diethylstilbestrol 126
 Diets 728
 Differential expression 237
 Differentiation 520, 1528
 Differentiation inducers 1556
 DNA adducts 226
 DNA damage 106
 DNA methylation 754
 DNA repair 489, 680, 1387
 DNA vaccine 374
 Docetaxel 170, 470, 1571
 Dose-response relationship
 1544
 Doxorubicin 367, 959, 1591
 DPC4/Smad4 253
 Drugs 1544
 Drug combination 579
 Drug delivery 157
 Drug resistance 186, 680, 959,
 1391
 Drug uptake 1528
 Ductal carcinoma *in situ* 539
 EB1089 686
 E-cadherin 1656
 EDTA 452
E6/E7 oncogenes 374
 EGCG 844
 Electrochemotherapy 565, 1272
 Electromagnetic fields 697
 Electroporation 565, 1272
 Embryonal carcinoma 340
 Endocrine tumours 253
 Endometrial cancer 31 (Suppl
 2), 126, 209, 545, 969, 975
 Endometrium 897
 Endothelial cells 565
 Endothelial growth factor
 receptors 926
 Endothelium 80
 England 1215
 Epidemiology 122, 392, 400,
 413, 910, 994, 1193, 1482
 Epidermal growth factor 936
 Epidermal growth factor
 receptors 1322, 1377
 Epidermoid cancers 37
 (Suppl 2)
 Epidoxorubicin 878
 Epigallocatechin gallate 844
 Epithelial tumours of the thymus
 51 (Suppl 2)
 Epitope peptides 94
 Epstein-Barr virus 783, 920,
 1227
 Epstein-Barr virus nuclear
 antigens 920
 ER α 686
 Erk-1 844
 Erk-2 844
 Erythropoietin 3 (Suppl 1), 24
 (Suppl 1)
 Erythropoietin mRNA 836
 Erythropoietin receptor mRNA
 836
 Ethics 413
 Etoposides 1453
 European guidelines 587
 European Organization for
 Research and Treatment of
 Cancer QLQ-H&N35 149
 EWS-Fli1 768
 Exercises 994
 Expression 504
 Extensive surgery 1602
 Familial cancer 388, 429
 Familial risks 969
 Fas 1330
 Fas-ligands 1330
 Females 1188
 Fenretinide resistance 1528
 Fibroblast growth factors 1656
 Fibroblast growth factor
 receptors 1656
 Fish consumption 1199
 Flavonoids 1391
 Flow cytometry 367, 626
 Fluorescence *in situ*
 hybridization 72
 Fluorescence-assisted mismatch
 analysis 482
 Fluorescent single-strand
 conformation polymorphism
 1505
 Fluorouracil 579
 5-Fluorouracil 263, 611, 878,
 1023, 1437, 1677
 5-Fluorouracil pharmacokinetics
 600
 Folate analogue 308
 Formalin fixed 1095
 α -Fucosyltransferase 1556
 Fusion transcripts 1087
 Gangliosides 1107
 GART inhibitors 308
 Gastric cancer 64, 186, 335,
 400, 470, 824, 878, 965, 1602
 Gelatinase 1076
 Gemcitabine 1179
 Gene expression 643
 Gene therapy 1252
 Genetic counselling 594
 Genetic epidemiology 388
 Genetic predisposition 776
 Genotyping 783
 Geographical variability 1482
 GF120918 42
 Glioblastoma 529
 Glioma 429, 1107
 Global indicators 1156
 Glomerular filtration 452
 Glucosyltransferase 1107
 β -Glucuronidase 550
 Glucuronide 550
 Glycogen phosphorylase 1497
 Glycoprotein hormones 808
 Glycosphingolipids 1107
 Goitre 832
 Growth inhibition 1640
 Guidelines 796
 Head and neck 149, 237, 504,
 776
 Health-related quality of life
 149
 Heat 120
Helicobacter pylori 965
 Hepatitis B 1207
 Hepatitis B virus 709
 Hepatitis C virus 709
 Hepatocarcinoma cells, human
 1556
 Hepatocellular carcinomas 74
 (Suppl 2), 709, 881, 886, 982,
 1377, 1640
 Hepatocyte growth factor 864
 Hepatocyte growth factor
 antagonists 864
 Hepatomas 743
 HER2/neu 94
 Hereditary breast cancer 116
 Hereditary non-polyposis
 colorectal cancer 1084
 Heridity 388, 429
 Hexadecylphosphocholine 1405
 High-dose chemotherapy 313,
 1348
 Histological type 400
 Histology 539
 HLA-A24 915, 1052
 HMG-CoA reductase inhibitors
 886
 HNPCC 1084
 Hodgkin's disease 55 (Suppl 2),
 381, 1227, 1339
 Hodgkin's disease, advanced
 1293
 Hormones, female 722
 Hormones and cancer 760
 HPA 819
 H-ras 374
 hSNF5 199
 hTERT 621
 Human papillomaviruses 791,
 796, 1616
 Human papillomavirus 16 1058
 Humans 1599
 Hyperinsulinaemia 417
 Hyperplasia 832
 Hyperplasia, atypical 209
 Hypoxia 626, 1070, 1280
Id3 352
 Immune escapes 1330
 Immunization 1207
 Immunohistochemistry 270,
 321, 539, 1095, 1377
 Immunosuppression 1624
 Immunotherapy 915, 1258,
 1443
In situ hybridization 783
In vitro assay 558
In vitro-to-in vivo correlations
 1424
In vivo proton magnetic
 resonance spectroscopy 1016
 Incidences 1084, 1207, 1463
 Indirubin 283

- Indirubin-3'-monoxime 283
 Infections 406, 1002
 Information needs 48
 Inherited predisposition to cancer 475, 478, 892
 Inhibitors 1535
 INI1 199
 5382insC 475
 Interferons 611, 1036, 1146
 Interleukin-1 329
 Interleukin-2 1036
 Interstrand crosslinks 1671
 Intraductal papillary-mucinous tumours 253
 Intratumoral injections 443
 Intraventricular therapy 1453
 Invasiveness 276, 558, 802
 Ionizing radiation 674, 776
 Irinotecan 579
 Isoprenyl transferases 1535
 Isoprenylation 1535
 Isothiocyanates 670
 Italy 196
- Jewish founder mutations 478
 JNK 670
 Juvenile polyposis 1314
- K562 959
 Kallikreins, human 643
 Kallikrein gene 5 643
 Ki-57 1064
 Ki-67 340, 1242
 K-ras 253, 1497
 Kupffer cells 1265
- LABC 1016
 Lactation 1472
 Laminin-5 659
 Laser capture microdissection 783
 Latency 920
 Latent membrane protein 920
 Latent membrane protein-1 1227
 Lectins 819
 Leucovorin 878
 Leukaemia 697, 990
 Leukaemia, acute lymphoblastic 11
 Leukaemia, acute myeloid 680
 Lewis antigen 1556
 Li-Fraumeni syndrome 116
 Liability 388
 Lifestyle factors 417
 Lipid mobilizing factor 1648
 Lipoic acid 1544
 Liposomal cisplatin 1029
 Liver cirrhosis 1265
 Local recurrences 244, 539
 Locally advanced breast cancer 1016
 Long-term survival 700
 Loss of heterozygosity 218, 226, 352, 381, 493, 739, 754, 1630
 Low risk breast cancer 164
 Low-dose computed tomography 25
 Lung cancer 25, 134, 392, 728, 892, 910, 1520
- Lung neoplasia 1199
 Lymph nodes 340
 Lymphocytes 776, 1339
 Lymphomas 990
- MAC 15A murine tumours 290
 Macrophages 626
 Magnetic resonance imaging 691, 1681
 Male breast cancer 482
 Malignant cells 87, 836
 Malignant melanoma of soft parts 535
 Malignant mesothelioma 49 (Suppl 2), 52
 Manganese 1681
 Manganese superoxide dismutase 529
 MAPK AP-1 926
 Mass screening 1477
 Matrilysin 1317
 Matrix metalloproteinases 1076, 1664
 Matrix metalloproteinase-1 276
 Matrix metalloproteinase-2 1363
 Matrix metalloproteinase-9 1363, 1488
 MCF-7 686
 MCF-7 human breast carcinoma cell line 367
MDR1 1405
 Medical lymphadenectomy 443
 Medullary thyroid carcinoma 808
 Megestrol 881
 Melanoma 81 (Suppl 2), 535, 819, 1036, 1146, 1466
 Melatonin 397
 Membrane potential 1099
 Meningioma 199
 Menstrual cycles 714
 Mesothelioma 49 (Suppl 2), 52
 Meta-analysis 303, 611, 722, 1150, 1188
 [¹³¹I]-Metaiodobenzylguanidine 460
 Metalloporphyrins 1681
 Metastasis 819, 1036, 1265, 1280, 1317, 1417, 1610
 Metastasis-related phenotypes 1556
 Metastatic medulloblastoma 1453
 Methotrexate resistance 11
 Micronucleus 674
 Microsatellites 253
 Microsatellite instability 232
 Microvessel density 1610
 Migrants 1215
 Migration 1564
 Miltefosine 1405
 Mitochondria 1099
 Mitochondrial permeability transition 1397
 Mitomycin 1150
 Mitomycin-C 1023
 Mitotic cell deaths 1272
 Mitoxantrone 859
 MLH1 321
- Monitoring 1301
 Morphine 587
 Mortality 392, 423
 Mouse 1107
 mRNA 276
 MSH2 321
 Mucin 1258
 Multidrug resistance 959, 1405
 Multiple myeloma 344, 621
 Multiple primary cancers 435
 Muscle proteolysis 1135
 Muscle wasting 946
 Mutations 199, 209, 335, 493, 704, 1344
 Myelotoxicity 19
 Myometrial invasion 545
- NACT 1016
 National surveys 1447
 Natural killer/T-cell lymphomas 920
 Neoadjuvant chemotherapy 1016
 Neoplasia 1242, 1681
 Neoplastic bone involvement 344
 Neoplastic meningitis 157
 Nested case-control studies 122, 975
 Neuroblastoma 460
 Neuroendocrine tumours 636, 808
 Neuron-specific enolase 903
 NIH 3T3 691
 Nitric oxide 1122
 Nitric oxide synthase 1122
 NK4 864
 Non-colon cancer 478
 Non-Hodgkins lymphoma 113, 303, 465, 499, 1115
 Non-small cell lung cancer 226, 903, 1150, 1179, 1372
 Non-smokers 134
 Non-steroidal anti-inflammatory drugs 965, 1188, 1412
 Δ Np73L 1235
 Nuclear lamins 512
- Oesophageal adenocarcinoma 748
 Oesophageal carcinoma 61 (Suppl 2), 276
 Oesophageal neoplasia 120
 Oesophagitis 120
 Oestradiol 975
 Oestrogens 126, 975
 Oestrogen receptors 1064
 Oestrogen receptor- α 545
 Oestrogen receptor- β 545, 1095
 OK-432 443
 Oral administration 42
 Oral cancer 739, 754, 1437
 Oral contraceptives 722
 Organ cultures 1076
 Oropharyngeal cancers 37 (Suppl 2)
 Osteopontin 951
 Osteoprotegerin 951
 Osteosarcomas 78 (Suppl 2), 951
- Ovarian cancer 18 (Suppl 2), 126, 170, 352, 594, 643, 704, 714, 1043, 1301, 1363, 1387, 1624
 Ovarian cancer cells 1551
 Ovarian neoplasia 1308
 Ovarian tumours 1528
 Overall survival 1610
 Overexpression 824
 Oxaliplatin 579
- P13K 1630
 p14ARF 1372
 p16 253, 504, 1372
 p16 methylation 982
 p21^{CIP1/WAF1} expression 1635
 P27^{Kip1} 1242
 p38 MAPK 851
 p53 253, 263, 529, 1052, 1070, 1497, 1505, 1551
 p53 antibodies 57
 p53 autoantibodies 52
 p53 expression 651
 p53 gene 739
 p53 genes 335
 p53 homologues 1235
 p53 mutations 226, 1635
 p73 antibodies 57
 P73L 1235
 p170 1520
 Paclitaxel 38, 42, 604, 1126, 1166, 1179, 1591
 Paediatrics 1029
 Palliative chemotherapy 1172
 Pamidronate 1586
 Pancreas 253
 Pancreatic adenocarcinoma 1656
 Pancreatic cancer 864
 Papillomavirus 1058
 Papillomavirus, human 374, 1219
 Paraffin-embedded materials 1095
 Parity 1219
 Participation 413
 Paternal occupational contacts 1002
 Patient information 8
 Patients' distress, oncologists' estimations of 179
 Patients' preferences 48
 PBSC transplantation 313
 PCR 1505
 Peptides 1052
 Perinatal factors 1466
 Peroxisome proliferator-activated receptor- γ 1640
 Peutz-Jeghers syndrome 1314
 P-glycoprotein 42, 367, 959
 Pheochromocytomas 636, 808
 Pharmacoeconomics 313
 Pharmacokinetics 3 (Suppl 1), 11, 11 (Suppl 1), 1029, 1453
 Phase I 604, 1029
 Phosphocholine 691
 Photodynamic diagnosis 33
 Photodynamic therapies 33, 1099
 Photosensitizers 33
 Phthalocyanine Pc 4 1099
 Picibanil 443
 PIN 1512

- PK11195 1397
 Plasma cells 621
 Ploidy 232
 Ploidy patterns 824
 Pluronic F68 90
 pO_2 histograms 626
 Point mutations 760
 Polarographic oxygen electrodes and sensors 1070, 1280
 Poly(ADP-ribose) polymerase 106
 Polycomb group genes 1372
 Polyethylene glycol 90
 Polymerase chain reaction 783
 Polymorphisms 743, 760
 Population pharmacokinetics 452
 Post-treatment cervical intraepithelial neoplasia 796
 Postmenopausal osteoporosis 1047
 Pravastatin 886
 Pre-cancerous lesions 1354
 Pre-operative immunotherapy 443
 Predictive assay 1070
 Preferences 1577
 Prenatal environment 1193
 Preoperative chemotherapy 1016
 Prevention 994
 Primary fibroblasts 674
 Probability models 704
 Prognosis 64, 186, 244, 276, 344, 423, 819, 903
 Prognostic factors 1488, 1602
 Prognostic markers 643
 Progression criteria 1301
 Proliferation inducers 1556
 Prostate cancer 202, 297, 859, 1344, 1076, 1417, 1571
 Prostate epithelia 1417
 Prostate specific antigens 760
 Prostatic intraepithelial neoplasia 202
 Proteases 936
 Protein breakdown 946
 Protein kinase C inhibitors 465
 Protein synthesis 1648
 Proteolysis-inducing factor 1599
 Proto-oncogenes 196
 Protracted infusion 5-fluorouracil 600
 $[^{31}P]$ -spectroscopy 691
 Psychiatric morbidity, detection of 1011
 Psychological co-morbidity 179
 Psychological distress 594
 Psychotherapeutic support 179
 PTEN 1630
PTEN 748
 10q23 748
 12q12-14 499
 Quality of life 297, 1156
 Quantitative RT-PCR 1664
 QLQ-H&N35 149
 Radiation therapy 489, 851
 Radionuclide imaging 367
 Radioresistance 489
 Radiosensitivity 892
 Radiosensitization 1122
 Radiotherapy 8, 31 (Suppl 1), 164
 Radon 134
 Railroads 697
 Randomized controlled trials 8, 878, 1156
 RANKL 951
Ras 691
ras mutations 982
 Ras superfamily 1535
 Reactive oxygen species 529, 1397
 Real-time quantitative polymerase chain reaction 783
 Rearrangements 193
 Recombinant human erythropoietin 31 (Suppl 1)
 Rectal cancer 69 (Suppl 2)
 Recurrences 1602
 5- α -Reductase 760, 1344
 Registration 1207
 Registries 435
 Renal function 452
 Reproductive factors 714
 Response to treatments 651, 1156
 Retinoblastoma endocrine tumours 990
 Retinoblastoma protein 520
 Retinoic acid receptors- β 1528
 Retinoids 1528
 Retinol 728
 Reverse transcriptase polymerase chain reaction 535
 Reviews 3 (Suppl 1)
 Right colon 969
 Risk factors 709
 Risks 417, 1199
 Rituximab 1115
RIZ(PRDM2) 743
 Rodent tumours 1280
 RT-PCR 72, 1087
 Rural population mixing 910, 1002
 SAFB 493
 Salivary gland tumours 42 (Suppl 2)
 Sarcomas 535, 1635
 SART3 antigens 915
 Scale comparisons 1156
 Schedule of administration 1023
 Scotland 1002
 Scottish trials 1146
 Screening 25, 1616
 Seasons 406
 Segregation analyses 429
 Selectivity 87
 Sensitivity 1477
 Sequence variations 791
 Sequential chemotherapy 470
 Serine protease 237
 Severe combined immunodeficient mouse 571
 Sex hormone-binding globulin 975
 SF-36 149
 Shared decision-making 1577
 Short-term infusion 604
 Small cell lung cancer 19, 38, 1166, 1447
 SMARCB1 199
 Smoking 141, 226, 1219
 Social class 179
 Social support 179
 Sodium phenylacetate 802
 Soft-tissue sarcoma 244, 1070, 1610
 Soft-tissue tumours 535
 Sojourn times 1477
 Solid pseudopapillary tumours 253
 Solid tumours 17 (Suppl 1)
 SOR Clinical Practice Guideline Program 1 (Suppl 2), 4 (Suppl 2)
 SOR project methodology 8 (Suppl 8)
 South Asians 1215
 Southern blot 193
 SPI-77 1029
 Squamous cell carcinoma 237, 504, 1235
 Squamous cell carcinoma antigens 851
 Squamous intraepithelial lesions 1058
 SRD5A2 760
 Staging 910
 Statistical models 1477
 Stimulation 1339
 Stroma 80
 Stromal fibroblasts 1664
 Stromelysin-1 659
 Strontium-89 297
 α -Subunit of glycoprotein hormones 808
 Suramin 558
 Survival 19, 232, 270, 303, 886, 1070, 1602
 Survival analysis 643
 Survivors 149
 Sweden 113
 Synovial sarcomas 1087
 Systematic reviews 1150
 Tamoxifen 881, 897
 Taxoids 1437
 T-cell leukaemia 571
 TCho 1016
 ^{99m}Tc -sestamibi 367
 TcR/CD3-zeta 1624
 Telomerase 504, 621, 631, 1551
 Telomere length 1348
 Temporal trends 1482
 Testicular cancer 1482
 ThinPrep cytology 360
 Thioctic acid 1544
 Thymal tumours 51 (Suppl 2)
 Thymidylate synthase 186
 Thyroid cancer 1586
 Time trends 400
 TNM classification 64
 Tobacco 392
 Topoisomerase I 106
 Topoisomerase II 106
 Topotecan 1043, 1166
 Toremifene 897, 1047
 Total choline 1016
 Toxicity 313
 TP53 mutations 116
 Transfection 768
 Transformation 499
 Transfusions 17 (Suppl 1)
 Transitional mucosa 1497
 Translation initiation 1520
 Trypsin 1363
 Tuberculosis 113
 Tumoral immune response 57
 Tumours 832
 Tumour antigens 57
 Tumour burden 344
 Tumour cells, cultured 1544
 Tumour expression 80, 1599
 Tumour invasion 1317
 Tumour oxygenation 1070
 Tumour progression 202
 Tumour recurrence 1610
 Tumour suppressor genes 352, 381, 493
 Tumour vascular architecture 1354
 Tumour virology 122
 Tumour-associated trypsin inhibitors 1363
 Tumour cell vaccine 374
 Twins 1460, 1463
 Tyrosine phosphorylation 670
 UFT 263
 Urban 910
 Uridine phosphorylase 1677
 Urinary bladder cancer 329, 1505
 Urokinase 329
 Vaccine efficiency 1564
 Variant liver oestrogen receptor transcripts 881
 Variations 1058
 Vascular endothelial growth factor 80, 844, 1252, 1322, 1610
 Videotapes 8
 Vinflunine 290
 Vinorelbine 290, 1437
 Vinyl chloride 982
 Viral interleukin-10 920
 Visual impairment 397
 Vitamin C 1544
 Vitamin D analogue 686
 Vitamin E analogue 87
 Vitamin K 1544
 Volume of clinical activity 1308
 Weekly chemotherapy 1166
 Weight loss 1599
 Wilms' tumour 990
 Women 392, 1193
 Zeta chain 1339